Jinshi Technology
Developer of gene sequencing technology. The company is focusing on the development of fourth-generation (nanopore) gene sequencers and reagents by using nanopore gene sequencing technology that provides current signals generated by the interaction of protein nanopores and nucleic acid bases. The device can convert the base sequences of DNA and RNA into current signals that can be easily measured, and achieve…
Funding snapshot
About
Developer of gene sequencing technology. The company is focusing on the development of fourth-generation (nanopore) gene sequencers and reagents by using nanopore gene sequencing technology that provides current signals generated by the interaction of protein nanopores and nucleic acid bases. The device can convert the base sequences of DNA and RNA into current signals that can be easily measured, and achieve convenient and fast sequencing goals at the single-molecule level. Founded in 2017, hea The company operates in Life Sciences > Life Sciences Platforms and Tools, Life Sciences > Genomics. Its business models include Genomics > Enabling Technologies > Instrument Systems > Nucleic Acid Analysis > Sequencing, Life Sciences Platforms and Tools > Instruments > Genomics > Nucleic Acid Sequencing. Founded in 2017. Headquartered in China, Chengdu. The company has raised funding at the Series B stage. Backed by investors including China Growth Capital, Sequoia Capital, Sinopharm Capital, Rongan Venture, Grand Mount Capital, Qianhai Derun Capital Management, Potential Capital, Co-win Ventures.
Business model
Genomics > Enabling Technologies > Instrument Systems > Nucleic Acid Analysis > Sequencing,
Life Sciences Platforms and Tools > Instruments > Genomics > Nucleic Acid Sequencing
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.